

Ellen Relkin is a partner at Weitz & Luxenberg, P.C. in New York City and Cherry Hill, New Jersey. She is certified by the New Jersey Supreme Court as a Certified Civil Trial Attorney. She has been elected as a “Super Lawyer” of New Jersey and New York as well as AV rated and selected for the Martindale-Hubbell Bar Register of Preeminent Women Lawyers. She is licensed to practice in New York, New Jersey, Pennsylvania, and the District of Columbia.

Ms. Relkin was most recently appointed as co-lead counsel by Hon. Nicholas Garaufis in *In re: Exactech Polyethylene Orthopedic Products Liability Litigation – MDL 3044*. In 2019, Ms. Relkin was appointed as co-lead counsel by the Hon. William H. Orrick in *In Re: JUUL Labs, Marketing Sales Practices, and Products Liability Litigation*, Northern District of California. In 2018, she was appointed to the Executive Committee in the Multi-District Litigation, *In Re: National Prescription Opiate Litigation*, Northern District of Ohio. In 2017, she was appointed as co-lead counsel, *In Re: Farxiga (Dapagliflozin) Products Liability Litigation*. She was also appointed as State Liaison Counsel by Hon. Indira Talwani as well as to the Plaintiffs’ Executive Committee. She also was appointed by Hon. Rachelle Harz as lead/liaison counsel in the multicounty litigation, *In Re: Stryker LFit CoCr V40 Femoral Heads Litigation*, Case No. 624. She was appointed by the Hon. Brian Martinotti to the Plaintiffs’ Executive Committee of the Plaintiffs’ Steering Committee in *In Re: Invokana (Canagliflozin) Products Liability Litigation*, US District Court, New Jersey. She was appointed by the Hon. Eldon E. Fallon to the Plaintiffs’ Steering Committee in *In Re: Xarelto (Rivaroxaban) Products Liability Litigation*, US District Court, Eastern District of Louisiana. She was court-appointed by the Hon. Brian Martinotti as lead counsel in the New Jersey *In Re: Stryker Rejuvenate/ABG II Modular Hip Litigation*. She was a member of the negotiating team for a settlement compensating 3,000 plaintiffs for an amount in excess of one billion dollars. Ms. Relkin is co-lead counsel in the DePuy ASR MDL litigation. In that capacity she played a key role in negotiating the \$2.5 billion settlement for 8,000 victims of the failed hip implant. She was a member of the trial team in the landmark Vioxx case *McDarby v. Merck*, that obtained a \$13.5 million verdict and successfully defended the compensatory verdict in writing and arguing the appeal before the New Jersey Appellate Division, 949 A.2d 223 (N.J. App. Div. May 29, 2008). This precedential case established that New Jersey recognized a heeding presumption in pharmaceutical product liability litigation.

Ms. Relkin is an elected member of the American Law Institute. She serves on the Board of Governors of the New Jersey Association for Justice, she is the Co-Chair of the Mass Tort Law Committee and Co-Chair of the Mass Tort I

Law Section of the New Jersey Association for Justice, she is also on the Pharmaceutical and Medical Device Subcommittee of the American Bar Association's Mass Torts Committee, as well as the Roscoe Pound Foundation. She also serves on the Board of Visitors of the University of California at Irvine Law School. She is a former chair of the Toxic, Environmental and Pharmaceutical Torts Section of the American Association of Justice.